Citius Pharma obtains partial deferral of milestone payment to Dr. Reddy's under LYMPHIR deal

Citius Pharmaceuticals, Inc.

Dr. Reddy's agreed to partial deferral without penalty of a milestone payment due Sep 9, 2024.
Milestone was triggered by FDA approval of LYMPHIR under the 2021 Asset Purchase Agreement.
Payment is by Citius Oncology, Inc.; Citius Pharmaceuticals, Inc. remains guarantor.
All other terms and conditions of the Asset Purchase Agreement remain unchanged.

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.